Silvia Alessi-Severini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5527216/publications.pdf

Version: 2024-02-01

393982 414034 1,154 58 19 32 citations g-index h-index papers 59 59 59 1726 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry, 2014, 14, 102.	1.1	174
2	Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis. Annals of Internal Medicine, 2020, 173, 417-425.	2.0	97
3	Ten Years of Antipsychotic Prescribing to Children: A Canadian Population-Based Study. Canadian Journal of Psychiatry, 2012, 57, 52-58.	0.9	89
4	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ, The, 2020, 370, m3342.	3.0	70
5	Use of benzodiazepines and related drugs in Manitoba: a population-based study. CMAJ Open, 2014, 2, E208-E216.	1.1	51
6	Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia. BMC Infectious Diseases, 2017, 17, 69.	1.3	44
7	Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996–2006. Psychiatric Services, 2008, 59, 547-553.	1.1	41
8	Atypical antipsychotics and hyperglycemic emergencies: Multicentre, retrospective cohort study of administrative data. Schizophrenia Research, 2014, 154, 54-60.	1.1	41
9	Prenatal antibiotics exposure and the risk of autism spectrum disorders: A population-based cohort study. PLoS ONE, 2019, 14, e0221921.	1.1	32
10	Psychotropic Drug Use before, during, and after Pregnancy: A Population-Based Study in a Canadian Cohort (2001-2013). Canadian Journal of Psychiatry, 2017, 62, 543-550.	0.9	30
11	High-performance liquid chromatographic analysis of methocarbamol enantiomers in biological fluids. Biomedical Applications, 1992, 582, 173-179.	1.7	28
12	Sustained Use of Benzodiazepines and Escalation to High Doses in a Canadian Population. Psychiatric Services, 2016, 67, 1012-1018.	1.1	28
13	Early childhood antibiotics use and autism spectrum disorders: a population-based cohort study. International Journal of Epidemiology, 2018, 47, 1497-1506.	0.9	26
14	Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. Diabetes Care, 2020, 43, 2444-2452.	4.3	26
15	Clozapine Prescribing in a Canadian Outpatient Population. PLoS ONE, 2013, 8, e83539.	1.1	25
16	Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia. Journal of Pain Research, 2016, Volume 9, 543-550.	0.8	24
17	NOVEL MEASURES OF BENZODIAZEPINE & DRUG UTILISATION TRENDS IN A CANADIAN PROVINCIAL ADULT POPULATION (2001-2016). Canadian Journal of Clinical Pharmacology, 2019, 26, e22-e38.	1.1	23
18	Evaluation of an Interchangeability Switch in Patients Treated With Clozapine. Journal of Clinical Psychiatry, 2006, 67, 1047-1054.	1.1	23

#	Article	IF	CITATIONS
19	Antibiotic Exposure in the First Year of Life and the Risk of Attention-Deficit/Hyperactivity Disorder: A Population-Based Cohort Study. American Journal of Epidemiology, 2019, 188, 1923-1931.	1.6	22
20	Prenatal antibiotic exposure and risk of attention-deficit/hyperactivity disorder: a population-based cohort study. Cmaj, 2020, 192, E527-E535.	0.9	17
21	Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors. Journal of Clinical Psychopharmacology, 2017, 37, 332-340.	0.7	16
22	Adverse Events in Elderly Users of Antipsychotic Pharmacotherapy in the Province of Manitoba. Journal of Clinical Psychopharmacology, 2013, 33, 24-30.	0.7	15
23	Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting. Clinical Drug Investigation, 2018, 38, 565-572.	1.1	15
24	Psychotropic Medication Use Before and During COVID-19: A Population-Wide Study. Frontiers in Pharmacology, 2022, 13, 886652.	1.6	15
25	Community Pharmacists' Perspectives on Dispensing Medications With the Potential for Misuse, Diversion, and Intentional Overdose: Results of a Province-Wide Survey of Community Pharmacists in Canada. Substance Use and Misuse, 2016, 51, 1724-1730.	0.7	14
26	Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a populationâ€based cohort study. Addiction, 2019, 114, 1791-1799.	1.7	14
27	Prescribing of psychotropic medications to the elderly population of a Canadian province: a retrospective study using administrative databases. PeerJ, 2013, 1, e168.	0.9	14
28	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and the risk of urosepsis: A multiâ€site, prevalent newâ€user cohort study. Diabetes, Obesity and Metabolism, 2020, 22, 1648-1658.	2.2	13
29	Annual trends in prevalence and incidence of autism spectrum disorders in Manitoba preschoolers and toddlers: 2004–2015. Canadian Journal of Public Health, 2019, 110, 476-484.	1.1	12
30	Elements and Enablers for Interprofessional Education Clinical Placements in Diabetes Teams. Canadian Journal of Diabetes, 2014, 38, 273-278.	0.4	11
31	Trends of COVID-19 incidence in Manitoba and public health measures: March 2020 to February 2022. BMC Research Notes, 2022, 15, 162.	0.6	11
32	High-Performance Liquid Chromatographic Determination of the Enantiomers of Flecainide in Human Plasma and Urine. Journal of Pharmaceutical Sciences, 1990, 79, 257-260.	1.6	10
33	Movement Disorders in Elderly Users of Risperidone and First Generation Antipsychotic Agents: A Canadian Population-Based Study. PLoS ONE, 2013, 8, e64217.	1.1	10
34	A Population-Based Study of the Use of Selective Serotonin Reuptake Inhibitors before and after Introduction of Generic Equivalents. Canadian Journal of Psychiatry, 2012, 57, 223-229.	0.9	9
35	Trends in the Use of Long-Acting Injectable Antipsychotics in the Province of Manitoba, Canada. Journal of Clinical Psychopharmacology, 2020, 40, 6-13.	0.7	9
36	Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study. BMC Health Services Research, 2021, 21, 758.	0.9	8

#	Article	IF	CITATIONS
37	Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 271s-308s.	0.9	7
38	Methocarbamol. Analytical Profiles of Drug Substances and Excipients, 1994, , 371-398.	0.0	5
39	Treating Children with ASD: The Perspective of Caregivers. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 74s-87s.	0.9	5
40	Risk of long-term benzodiazepine and Z-drug use following the first prescription among community-dwelling adults with anxiety/mood and sleep disorders: a retrospective cohort study. BMJ Open, 2021, 11, e046916.	0.8	5
41	The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study. ClinicoEconomics and Outcomes Research, 2016, 8, 207.	0.7	4
42	Trends of Utilization of Antiseizure Medications Among Pregnant Women in Manitoba, Canada: A 20-Year Population-Based Study. Frontiers in Pharmacology, 2022, 13, 871136.	1.6	4
43	New antidepressant use in older adults: a Canadian population-based study (1997–2013). Aging and Mental Health, 2017, 21, 720-729.	1.5	3
44	Movement Disorders in Children and Adolescents Receiving Antipsychotic Pharmacotherapy: A Population-Based Study. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 892-896.	0.7	3
45	Developing key performance indicators for prescription medication systems. PLoS ONE, 2019, 14, e0210794.	1.1	3
46	Use of smoking cessation products: A survey of patients in community pharmacies. Canadian Pharmacists Journal, 2017, 150, 326-333.	0.4	2
47	Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort. Frontiers in Pharmacology, 2022, 13, .	1.6	2
48	Validity of the days supply field in pharmacy administrative claims data for the identification of blister packaging of medications. Pharmacoepidemiology and Drug Safety, 2017, 26, 1540-1545.	0.9	1
49	Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. CMAJ Open, 2018, 6, E637-E642.	1.1	1
50	Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study. Drugs - Real World Outcomes, 2022, , .	0.7	1
51	Second-Generation Antipsychotic Agents: A Review of Safety Profiles. Current Psychiatry Reviews, 2012, 8, 49-68.	0.9	0
52	P1â€439: Incidence of Mood and Anxiety Disorders and Psychotropic Use in Spousal Caregivers of Dementia: A Populationâ€Based Study. Alzheimer's and Dementia, 2016, 12, P603.	0.4	0
53	O3â€06â€01: Incidence of Mood and Anxiety Disorders and Psychotropic use in Spousal Caregivers of Dementia: A Populationâ€Based Study. Alzheimer's and Dementia, 2016, 12, P298.	0.4	0
54	The Out-Of-Pocket Cost Burden of Prescription Drugs: A Pan-Canadian Comparison. Value in Health, 2018, 21, S120.	0.1	0

#	Article	IF	CITATIONS
55	Reply to Clozapine Interchangeability Issues. Journal of Clinical Psychiatry, 2007, 68, 1311.	1.1	0
56	Cost Interactions in Healthcare. SSRN Electronic Journal, 0, , .	0.4	0
57	'Irrelevant' Costs in Healthcare: A Population Study of the Treatment of Schizophrenia in the Province of Manitoba. SSRN Electronic Journal, 0, , .	0.4	O
58	Seeking the Balance between Harm and Benefit: The Role of Pharmacosurveillance in Choosing the Drugs We Should Take. Healthcare Policy, 2011, 6, 100-3.	0.3	O